The aim of this study is to determine a multidimensional signature (integrating frailty and patient-reported outcomes measures (PROMs) at entry into stage 4B/5 CKD) to improve prediction of renal death (dialysis, transplantation, conservative management, death).
Patients with CKD stage 4B or 5 (first consultation with GFR < 20 mL/min /1.73 m2 in CKD-EPI 2009).
Fluency in French
Membership of a French social security scheme
Non-opposition from the subject to participate in the study
Subjects with limited legal capacity.
Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.
Subjects with no social security coverage.
Subjects judged by the investigator to be unlikely to comply with study procedures
The population consisted of patients aged 75 years and older with stage 4B/5 chronic kidney disease (GFR\<20ml/min/1.73m²), who spoke French and were under the usual care of the nephrology units involved in the study.
Case-only
Prospective
Not listed
Overall survival
Time between first visit (entry into stage 4B/5) and death from any cause. Living patients will be censored at the date of last news. Entry into CKD 4B/5 is defined as the first kidney disease follow-up visit for which the patient has an eGFR strictly below 20 ml/min/1.73m2.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
